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Accurate and standardized methods for the quantitative measure-
ment of BCR–ABL1 are a prerequisite for monitoring of treatment
response in t(9;22)-positive leukemia. Here, we describe a novel
multiplex assay system based on the proven TaqMan and Armored
RNA technologies and optimized for sensitive detection of three
BCR–ABL1 fusion transcripts and ABL1 in a single reaction.
Analytical experiments conﬁrmed the absence of signiﬁcant
competition between the simultaneous ampliﬁcation reactions
and established the sensitivity, linearity and precision of the assay.
Comparative studies with 115 clinical specimens resulted in high
qualitative and quantitative agreement with independent singleplex
laboratory-developed tests routinely used in clinical testing. Direct
comparison with a reference laboratory calibrated to the inter-
national scale (IS) demonstrated minimal analytical bias between
methods and an overall accuracy and precision within the
performance range required for quantitative measurement of
BCR–ABL1 on the IS. We conclude that detection of e1a2, b2a2,
b3a2 and ABL1 can be achieved in a multiplex assay format
compatible with IS reporting. Further clinical validation of the assay
could improve the operational efﬁciency of clinical laboratories,
increase their adherence to current recommendations for b2a2/
b3a2 reporting on the IS and provide for the ﬁrst time an
opportunity to standardize e1a2-monitoring results.
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Introduction
The development and clinical use of the tyrosine kinase inhibitor
imatinib mesylate has fundamentally altered the management of
chronic myeloid leukemia patients. Over the past 10 years, a
reasonable consensus has been reached in the United States and
Europe for treatment and monitoring of residual disease during ﬁrst-
line therapy.
1–4 The International Randomized Study of Interferon vs
STI571 (IRIS) and follow-up studies have demonstrated that
achieving major molecular response (MMR), or a 3-log decrease
in BCR–ABL1 expression from a standard baseline level, was a key
clinical outcome.
4 Sensitive molecular methods to quantify the
expression levels of BCR–ABL1 fusion transcripts have therefore
emerged as valuable tools for the assessment of treatment response
and detection of relapse.
2,3 As many different preanalytical,
analytical and reporting methods are used worldwide, it was
proposed in 2005 to harmonize quantitative BCR–ABL1 results on
an international scale (IS) anchored to the standard baseline level
from the IRIS trial (100% IS), with MMR corresponding to 0.1% IS.
3
Subsequent international collaborative studies demonstrated that
protocol standardization and establishment and validation of
conversion factors (CFs) between ﬁeld methods and IS Reference
Laboratories improved harmonization and MMR concordance
rates.
5,6 This approach has been particularly successful in Europe
through the establishment of National Reference Laboratories
harmonized to the IS in 24 different countries.
7 Collectively, these
publications also provided clear recommendations on the optimal
preanalytical parameters and analytical performance characteristics,
such as sensitivity, linearity, accuracy and precision, that are
required for quantitative measurement of BCR–ABL1 and reporting
on the IS.
3,5–7
A prerequisite for standardization is the use of an appropriate
endogenous control gene, most often ABL1,
3,8 and reporting of the
BCR–ABL1 to control gene ratio. One limitation of this approach is
the difﬁculty to fully control the efﬁciency of independent PCR
reactions for BCR–ABL1 and the control gene, and to ensure that
unrelated results can be combined in a single-ratio value. The
inclusion of additional PCR reactions in every run to test each
positive/negative control and to build standard curve(s) for the
control gene(s) can also decrease the number of clinical samples
tested per batch and reduce the operational efﬁciency of clinical
l a b o r a t o r i e s .M o r e o v e r ,t h eI R I St r i a la n dI Sh a r m o n i z a t i o ne f f o r t
exclusively focused on the BCR–ABL1 fusion transcripts resulting
from the major break point (e13a2 and e14a2, also named b2a2 and
b3a2 in this manuscript). Yet, other fusion transcripts resulting from
t(9;22), such as e1a2, are clinically relevant. For example, Verma
et al.
9 recently showed that chronic myeloid leukemia expressing
only e1a2, although rare, are associated with inferior outcome and
should be closely monitored during therapy with tyrosine kinase
inhibitor. In acute lymphoblastic leukemia, where e1a2 represents
70% of t(9;22)-positive cases, correlation between BCR–ABL1
expression levels and long-term outcome is less clear and much
work is still needed to deﬁne appropriate BCR–ABL1 response
criteria.
10 Standardization of e1a2 monitoring assays for which
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step toward addressing these clinical needs. One potential solution
to overcome the above limitations would be to detect e1a2, b2a2
and b3a2, as well as an endogenous control in a single-well
reaction. In this report, we describe such an assay and show that it
can meet the stringent performance characteristics that have been
established with the well-characterized singleplex assays currently
used in routine clinical testing.
Materials and methods
Samples
Peripheral blood or bone marrow specimens from leukemia
patients were collected, processed and archived at two
independent sites. Specimens processed at the Hospital of the Received 10 February 2011; accepted 15 February 2011
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www.nature.com/bcjUniversity of Pennsylvania (HUP, method 1, n¼33) were tested
with the BCR/ABL1 Quant assay at HUP on a standard 7500
Real-Time PCR System (Applied Biosystems, Carlsbad, CA,
USA). Each specimen had previously been tested with a
laboratory-developed test (LDT) consisting of two quantitative
singleplex assays for the ABL1 endogenous control or BCR–
ABL1 major fusion transcripts (b2a2/b3a2). Specimens acquired
from an independent clinical laboratory and previously char-
acterized with independent singleplex LDTs for ABL1 and the
major (b2a2/b3a2) or minor (e1a2) BCR–ABL1 fusion transcripts
(method 2, n¼82) were tested at Asuragen Inc. (Austin, TX,
USA) on a 7500 Fast Dx Real-Time PCR System (Applied
Biosystems). All human specimens in this study were de-
identiﬁed and evaluated according to protocols approved by
their respective institutions. No results were reported to
physicians or patients or used for treatment decision, and no
protected health information or other information identifying
patients was released.
Total RNA was puriﬁed from translocation-positive leukemic
cell lines (SUP-B15/e1a2, BV173/b2a2, or K562/b3a2) or from
the t(9;22)-negative leukemic cell line HL-60 using an optimized
laboratory-validated method based on the mirVana miRNA
Isolation Kit (Ambion, Carlsbad, CA, USA). When indicated,
positive cell line RNA was diluted mass-to-mass in a back-
ground of negative cell line RNA keeping the concentration of
total RNA constant. Samples from the First World Health
Organization International Genetic Reference Panel for quanti-
tation of BCR–ABL mRNA, comprising four dilution levels of
freeze-dried K562 cells diluted in HL-60 cells, were processed
using 600ml of RLT buffer (Qiagen, Valencia, CA, USA) as
recommended in White et al.
11 RNAs corresponding to speciﬁc
fusion transcripts were prepared using standard in vitro
transcription methods. The concentration and purity of every
sample in this study was evaluated at 260 and 280nm using
standard spectrophotometric methods.
Multiplex reverse transcription-PCR
Multiplex reactions were performed in 96-well plates using the
BCR/ABL1 Quant kit (for research use only, not for use in
diagnostic procedures) according to the instructions for use
(Asuragen Inc.). Brieﬂy, the kit consists of two reverse transcription
(RT) reagents, three PCR reagents and four calibrators. Up to 5ml
of RNA was reverse transcribed into complementary DNA (251C,
10min; 421C, 45min; 931C, 10min) on a GeneAmp PCR System
9700 (Applied Biosystems) using 8mlo fR Tb u f f e ra n d2 mlR T
enzyme mix in a ﬁnal volume of 20ml. Twenty-ﬁve percent (5ml)
of the complementary DNA was then ampliﬁed by multiplex PCR
(371C for 15min, 951C for 10min, followed by 45 cycles of 951C
for 15s and 601C for 1min) on a 7500 real-time PCR instrument
(Applied Biosystems) using 16.5ml quantitative PCR buffer, 2.5ml
primer/probe mix and 0.5ml of provided AmpliTaq Gold. The
Armored RNA Quant calibrators were diluted 1:10 with the
provided diluent and heat denatured for 5min at 751C
immediately before the RT reactions.
Four-point standard curves were generated in triplicate for
each color channel in every run (12 reaction wells). As the assay
detects e1a2, b2a2 and b3a2 in the FAM channel with similar
efﬁciency, a unique BCR–ABL1 standard curve was used to
quantify all three fusion transcripts. Cycle threshold (Ct) values
for each target were determined within the log-linear phase
of the ampliﬁcation curves after setting the appropriate baseline
in each color channel of the 7500 using the manual baseline
method. Standard curves, Ct values and copy numbers for
each tested sample were automatically generated by the
7500 software.
Size fractionation
For capillary electrophoresis (CE) analysis, the PCR products
stored in the dark below  151C were diluted 1:50 in water and
1ml of diluted material was combined with 0.5ml of GeneScan
500 ROX Size Standard (Applied Biosystems) and 13.5mlo f
Hi-Di Formamide (Applied Biosystems). After heat denaturation
at 951C for 2min, samples were transferred on a cold block,
quickly centrifuged and analyzed on a 3130xl Genetic Analyzer
equipped with 36cm POP-7 capillaries (Applied Biosystems)
using the following conditions: pre-run¼15kV for 180s;
temperature¼601C; injection¼1.6kV for 20s; run¼15kV for
50min; and other settings¼default. Raw data (.fsa ﬁle) were
analyzed with the GeneMapper Software V4.0 (Applied
Biosystems). The calculated sizes for b2a2, e1a2 and b3a2
amplicons are 90, 119 and 160bp, respectively, and the
observed sizes were 88, 116 and 166bp, respectively.
Data analysis
Ct values and copy numbers generated by the 7500 software
were processed with the BCR/ABL1 Quant XL data analysis tool
to automatically calculate percent ratios. Samples with o5.10
4
copies of ABL1 per RT reaction were ﬂagged for review, and
quantitative results were not reported if the BCR–ABL1 copy
number was o50 copies. Samples with o10
4 copies of ABL1
per RT reaction were excluded and retested. When appropriate,
raw Ct or log (% ratio) were further analyzed in Excel (Microsoft
Corp., Redmond, WA, USA) to generate graphic representations
and linear regression data. Mean bias, CF, percent agreement
and MMR concordance rate were calculated according to
Branford et al.
5 The percent agreement between methods in
Figure 3 was calculated by scoring the qualitative results
obtained by CE analysis with the BCR/ABL1 Quant amplicons
(major or minor) versus the quantitative results obtained with
independent LDTs speciﬁc either for the major or minor BCR–
ABL1 fusion transcripts.
To assess analytical precision, two samples covering a 3-log
percent ratio range were tested on 5 independent days by three
different operators (runs 1 to 3 by operator 1, run 4 by operator 2
and run 5 by operator 3). The medium-high positive sample (1 in
10
2 cell line dilution, expected percent ratio at about 5%) was
tested in triplicate and the low positive sample (1 in 10
5 dilution,
expected percent ratio at about 0.005%) was tested in
quadruplicate. For the low positive sample, where the highest
variability is expected and some replicates can be below the
assay limit of quantitation (LOQ), the largest outlier from the daily
median in each run was excluded so that the three replicates per
run would be analyzed. Standard deviations and coefﬁcients of
variation were calculated according to approved consensus
guidelines for the evaluation of quantitative devices.
12
Results
Assay design and rationale
To enable both qualitative and quantitative measurement of
BCR–ABL1 in a multiplex format, the three fusion transcripts
e1a2, b2a2 and b3a2 are detected by a single TaqMan probe
speciﬁc for ABL1 exon a2 in the FAM channel of a real-time
instrument (Figure 1). For ampliﬁcation of e1a2 or b2a2/b3a2,
the assay contains two sense primers speciﬁc for BCR exons e1
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has a different size and shares an antisense primer speciﬁc for
ABL1 exon a2 carrying a 50 label to enable subsequent size
separation by CE. This design does not enable the detection of
other rare fusion transcripts, such as e1a3, e13a3 or e14a3. Total
ABL1 (that is, ABL1 and BCR–ABL1) is detected in the ROX
channel of the real-time instrument using a pair of primers and a
probe speciﬁc for the exon 10/exon 11 junction. ABL1 was
chosen as the endogenous control based on its documented
expression and stability in leukemia samples.
8,13 Because the
assay is multiplexed, four-point standard curves for both ABL1
and BCR–ABL1 can be built by testing only four Armored RNA
Quant calibrators provided with the kit (Figure 2a). Finally, the
assay can also detect a non-human sequence called Norm. This
synthetic transcript can be spiked as a nuclease-resistant
Armored RNA Quant molecule into test specimens before
RNA extraction and be codetected by the assay in the Cy5
channel of the real-time instrument (Figure 1). This optional
feature may be used as a qualitative or quantitative process
control, for example, to determine the normalized copy number
of BCR–ABL1 per unit of white blood cells; however, this assay
feature was not evaluated in this study. We focused exclusively
on the key performance metrics required to determine whether
the current research tool would be appropriate for the
quantitative measurement of BCR–ABL1 to ABL1 ratio on the IS.
Evaluation of analytical performance
Analytical performance was ﬁrst evaluated using synthetic RNA
targets prepared by in vitro transcription. Speciﬁcity was
demonstrated by detection of BCR–ABL1, ABL1 and Norm in
their respective ﬂuorescence channels (FAM, ROX or Cy5) with
no cross-detection between the three color channels of the
instrument and no cross-reactivity between the different targets
(data not shown). No Ct value could be measured when testing
other synthetic RNAs corresponding to various leukemia fusion
transcripts resulting from t(1;19), t(4;11), t(8;21), t(12;21),
t(15;17) or inv(16) (data not shown). Serial dilution of e1a2,
b2a2, b3a2, ABL1 and Norm synthetic RNAs from 10
8 to 10
1
copies per RT reaction showed that the assay was linear across
7 logs with similar R
2 and linear regression curves (Figure 2b).
Each target was reproducibly detected at 50 copies per RT with
495% positivity (Ct below 40), suggesting a LOQ at least
equivalent to 10–15 copies per PCR (25% of the RT reaction
input). At lower input, the assay was still linear with 450%
positivity at 10 copies per RT reaction, suggesting a limit of
detection of at least 2–5 copies per PCR.
Linearity, limit of detection and LOQ were further assessed
in a multiplex format by diluting total RNA puriﬁed from
translocation-positive leukemic cell lines (SUP-B15/e1a2,
BV173/b2a2 or K562/b3a2) into a background of total RNA
puriﬁed from the t(9;22)-negative leukemic cell line HL-60 and
keeping the total RNA input constant. The assay output (mean
BCR–ABL1 to ABL1 ratio) was linear across 6 logs of dilution
with similar R
2 and linear regression curves for each fusion
transcript (Figure 2c). The individual Ct values, demonstrating
linear Ct response and no loss of sensitivity or linearity at low
BCR–ABL1 input, are shown in Supplementary Figure 1. Greater
than 95% positivity was obtained at 1 in 10
5 dilution (percent
ratio between 0.001 and 0.005%) and 450% positivity was
obtained at 1 in 10
6 dilution (percent ratio below 0.0005%).
All samples detected by real-time RT-PCR (Ct below 40) were
also positive by CE analysis, and no BCR–ABL1 signal was
detected in HL-60 RNA (data not shown). Additional experi-
ments conﬁrmed the assay’s LOQ between 500 and 1500ng
RNA input and the absence of non-speciﬁc signal with genomic
DNA puriﬁed from t(9;22)-positive cell lines (data not shown).
Evaluation of analytical precision
Cell line RNA samples were also used to estimate assay
precision. First, independent dilutions covering a range of
percent ratios from about 10 to 0.005% were tested in duplicate
(Figure 2d). All duplicate results were within 3.7-fold of each
other, with 85% of the duplicates within 2-fold and the largest
differences observed for the lowest percent ratios below 0.02%
(Figure 2d). Calculation of the 95% limit of agreement on this set
indicated that 95% of the duplicate results were expected to be
within plus or minus 2.4-fold of the mean. Analytical precision
was further evaluated by testing samples covering a 3-log range
on multiple days (see Materials and methods). In ﬁve indepen-
dent runs performed by three different operators, slope, intercept
and R
2 for the BCR–ABL1 and ABL1 standard curves were highly
reproducible, and the expected 3-log difference between the
high and low sample levels was observed in every run (Table 1).
An estimate of assay precision based on the standard deviation
of the daily means and corresponding coefﬁcients of variation
was 20.8 and 52.7% for the high and low levels, respectively.
The exact within-run variability (repeatability precision or Sr),
between-day/run variability (combined day and run precision or
Sdd) and within-device variability (total precision or ST) are
shown in Table 2.
Comparison with singleplex clinical assays
Assay performance was evaluated with 115 total RNA samples
archived at two independent sites, each using their own
preanalytical and analytical methods to collect, process and
test the samples with singleplex quantitative LDT for ABL1 and
b3a2
b2a2
a2
e13
e14 e13
a2
FAM
e1a2
ABL1
e1
a10
FAM
FAM
Norm
ROX
Cy5
a11
a2
Figure 1 Primers and probes design. The positions of each primer
relative to BCR (gray box) and ABL1 (white box) exonic sequences are
indicated by arrows. The relative positions of each of the three
TaqMan probes, carrying a unique combination of dye and quencher
(K) for real-time amplicon detection in the FAM, ROX or Cy5 color
channels of the 7500 instrument, are also shown. The reverse primer
speciﬁc for ABL1 exon a2 carries a 50 label (’) to enable subsequent
detection of the BCR–ABL1 amplicons in the FAM channel of a CE
instrument. Primer and probe sequences were checked against
databases and designed to avoid common polymorphisms such as
the T to C substitution in BCR exon 13. Norm (dark gray box) is a
synthetic sequence with no signiﬁcant homology to known genomic
sequences.
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Blood Cancer JournalBCR–ABL1 e1a2 or b2a2/b3a2 (see Materials and methods).
The clinical set represented a broad range of specimen type,
BCR–ABL1 expression level and fusion transcript identity
(Figure 3a). All of the 115 total RNA samples tested in singleton
with the BCR/ABL1 Quant assay had acceptable ABL1
copy number (Supplementary Table 1) and generated BCR–
ABL1-positive results, with percent ratios ranging over
4 logs (Figure 3b). Quantitative analysis was performed on
103 specimens only, as 12 specimens had no percent ratio
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Figure 2 Analytical performance. (a) Multiplex standard curves using Armored RNA Quant technology. The four calibrators, each containing
various levels of BCR–ABL1 (e1a2), ABL1 and Norm targets and covering 5 logs of linear dynamic range overall, were tested in triplicate. The
three resulting four-point standard curves and corresponding R
2 automatically generated by the 7500 instrument’s software are shown.
(b, c) Representative examples of analytical sensitivity and linearity with ﬁve synthetic RNAs prepared by in vitro transcription or three leukemic
cell line RNAs diluted in a background of HL-60 total RNA (1500ng input). The graphs show the mean values obtained from duplicate testing
(10
8,1 0
6 or 10
4 copies of synthetic target; cell lines undiluted or diluted 1 in 10
2 or 1 in 10
4), triplicate testing (100 or 50 copies of synthetic target;
cell lines diluted 1 in 10
5) or quadruplicate testing (10 copies of synthetic target; cell lines diluted 1 in 10
6). (d) Results from duplicate testing using
40 independent cell line RNA dilutions at 1500ng input. The graph shows the percent ratio for the second measure plotted against the percent ratio
of the ﬁrst measure and the theoretical equality line (ﬁrst measure¼second measure).
Table 1 Results from ﬁve independent runs
Day 1 Day 2 Day 3 Day 4 Day 5 Mean % CV
BCR–ABL1
Slope  3.41  3.58  3.33  3.35  3.22  3.38 3.9
Intercept 41.89 42.89 41.22 41.86 40.87 41.75 1.9
R
2 0.994 0.995 0.991 0.995 0.994 0.994 0.2
ABL1
Slope  3.52  3.41  3.41  3.56  3.5  3.48 1.9
Intercept 41.1 41.05 41.06 41.84 40.61 41.13 1.1
R
2 0.998 0.998 0.999 0.999 0.999 0.999 0.1
% Ratio
10
2 Dilution 5.67 5.68 7.23 4.77 4.20 5.51 20.8
10
5 Dilution 0.0077 0.0063 0.0096 0.0018 0.0038 0.0059 52.7
% Ratio difference (log) 2.87 2.95 2.88 3.42 3.04 3.03 7.5
Abbreviation: CV, coefﬁcients of variation.
Table 2 Calculation of assay precision
Within-run Between-day/run Total precision
Sr %C V Sdd %C V ST %C V
10
2 Dilution 0.84 15.3 1.04 18.9 1.34 24.3
10
5 Dilution 0.0035 74.1 0.0011 24.3 0.0037 78.0
Abbreviation: CV, coefﬁcients of variation.
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positive but below the LOQ of the LDT). With the multiplex
assay, these 12 specimens were all above the limit of detection
(16–123 copies of BCR–ABL1 per RT, median¼70 copies) and
8 specimens were above the LOQ (57–123 copies per RT). The
paired correlation between each LDT and the BCR/ABL1 Quant
assay was 0.97 with 95% limits of agreement of plus or minus
3.2-fold for method 1 and 4.0-fold for method 2 (Figure 3b). The
PCR amplicons were further resolved by CE analysis to
determine the type of fusion transcript(s) detected during the
real-time PCR (Figure 3c). There was perfect agreement between
the quantitative LDTs and the BCR/ABL1 Quant assay for the
identiﬁcation of minor (e1a2) versus major (b2a2/b3a2) fusion
transcripts. All 12 e1a2-positive specimens were correctly
identiﬁed, and about 15.5% (16/103) of the specimens reported
as positive for a major fusion transcript by the LDTs showed
coexpression of b2a2 and b3a2 (Figure 3c, bottom panel).
Comparison with the IS
Compatibility of the assay with the IS was evaluated by testing
reference materials with known IS percent ratios determined by
an international group of IS-standardized laboratories.
11 All four
samples tested in triplicate showed robust and reproducible Ct
values, with a linear regression curve characteristic of a 10-fold
serial dilution (Figure 4a). The calculated mean percent ratios
were perfectly correlated (Figure 4b). The slope (1.03) and
overall measured fold change (3.09 log) were consistent with the
previously reported IS percent ratios, suggesting appropriate
assay performance in terms of sensitivity and linearity.
To fully characterize the potential bias between the multiplex
assay and the IS, 20 representative mixed cell line RNA samples
were tested with BCR/ABL1 Quant and an IS reference method
(International IS Reference Laboratory, Adelaide, Australia).
Bland and Altman analysis
5 showed that the mean bias between
methods was 0.017, corresponding to a preliminary CF of 1.04
(Figure 5a). One hundred percent (20/20) of the corrected
percent ratios obtained with the BCR/ABL1 Quant assay were
within ﬁvefold of the IS, 95% (19/20) were within threefold and
80% (16/20) were within twofold. The paired correlation
between methods was 0.97, with 95% limit of agreement of
plus or minus 3.6-fold (Figure 5b). After 14 months, a valida-
tion experiment was performed using an independent lot of
BCR/ABL1 Quant reagents. If there were no changes between
reagent lots and methods, the bias after conversion should be
close to 0 and the antilog of the bias (CF) should be close to 1.
Results showed a mean bias of  0.019 corresponding to a CF of
0.96, with 95% limit of agreement of plus or minus 4.2-fold after
conversion (Figure 5b). A secondary analysis of the mean bias
between methods for the pooled 40 samples before conversion
also showed an overall CF of 0.99, with 95% limit of agreement
of plus or minus 3.9-fold (Figure 5b).
We also examined the assay’s ability to accurately classify
specimens as MMR positive (p0.1% IS) or MMR negative
(40.1% IS) for the set of 40 samples described above.
According to the IS reference method, 57.5% (23/40) of the
samples were MMR negative and 42.5% were MMR positive
(Figure 5b). The overall agreement between the IS reference
method and the BCR/ABL1 Quant assay was 87.5% (35/40;
Figure 5b), with a corresponding MMR concordance rate of 74%
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Figure 3 Comparison with existing LDTs. (a) Description of sample set and summary of results. (b) Quantitative analysis on 103 archived total
RNA samples with LDT results ranging from 4100 to about 0.001% ratio. Percent ratio and calculated paired Pearson correlation values are
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sum of true MMR positive, false MMR negative and false MMR
positive). A closer examination of the ﬁve misclassiﬁed samples,
two false MMR positives and three false MMR negatives showed
little difference between the methods (Figure 5c). All samples
misclassiﬁed had a BCR/ABL1 Quant IS percent ratio within the
95% limit of agreement between methods, independently of the
lot of BCR/ABL1 Quant reagent used.
Discussion
The research assay described here is designed and optimized to
enable quantitative measurement of both ABL1 and BCR–ABL1
in a single well of a real-time PCR instrument. One feature of
multiplex assays that is often considered a daunting technical
challenge is the potential loss of sensitivity or linearity when one
of the targets is present at low copy number. The efﬁcient
detection of BCR–ABL1 at low copy number in a high
background of ABL1 was demonstrated by a linear Ct response
in serial dilution series (Figures 2 and 4, Supplementary Figure 1)
and a high correlation with different singleplex assays including
an IS reference method (Figures 3 and 5). Further, parallel
reactions with the multiplex assay or an assay containing only
the BCR–ABL1-speciﬁc primers and probe resulted in similar
Ct values (data not shown). A signiﬁcant competition between
the BCR–ABL1 and ABL1 ampliﬁcation reactions in the
multiplex assay can therefore be ruled out. Serial dilutions of
well-characterized cell lines have been shown to generate a
range of percent ratios similar to leukemic specimens
14 and
were used here to establish that the multiplex assay can
reproducibly detect BCR–ABL1 across a broad linear dynamic
range. However, it is important to note that the assay detects
total ABL1 at the junction between exons 10 and 11 (Figure 1).
Therefore, high BCR–ABL1 levels in undiluted RNA can
artiﬁcially affect the percent ratio. Below 10% dilution, the
contribution in total ABL1 from the t(9;22)-positive cell lines is
negligible relative to the ABL1 contributed by HL-60 and should
not impact the measured percent ratios. This effect was
evidenced with the BV173 cell line that lacks expression of
normal ABL1 and instead expresses an ABL1–BCR fusion
transcript commonly found in t(9;22)-positive chronic myeloid
leukemia patients.
15,16 As expected, undiluted BV173 RNA
reproducibly generated percent ratios higher than with the two
other cell lines (around 100%, that is, total ABL1¼BCR ABL1)
and no signiﬁcant differences between the cell lines were
observed after 10-fold serial dilutions (Figure 2c and Supple-
mentary Figure 1).
Multiplexing quantitative assays can also provide speciﬁc
advantages. For example, multiplex assays have the potential to
reduce the burden of validation and operator training for
independent assays, to increase the number of samples tested
per run, to improve the laboratory throughput and, overall, to
streamline the laboratory workﬂow. As the identity of BCR–
ABL1 fusion transcript is in general determined at initial
diagnosis
3 by independent qualitative PCR methods, the BCR/
ABL1 Quant assay does not discriminate between e1a2, b2a2
and b3a2 fusion transcripts and a single quantitative BCR–ABL1
result is generated. However, the assay can distinguish the three
BCR–ABL1 fusion transcripts with the optional CE reﬂex-testing
step. The multiplex assay may also provide additional beneﬁts
relative to previously described quantitative LDTs compatible
with CE.
17,18 For example, all reagents are manufactured under
current good manufacturing practises and are optimized to
reduce the number of pipetting steps and to streamline the assay
workﬂow (see Materials and methods). The assay also includes
AmpliTaq Gold polymerase and Armored RNA Quant calibra-
tors for the establishment of four-point multiplex standard curves
for each target detected by the assay (Figure 2a). Armored RNAs
are stable, nuclease resistant and precisely quantiﬁed synthetic
RNAs already widely used as controls and standards in clinical
molecular infectious disease testing.
19 Unlike plasmid stan-
dards, these RNA molecules enable assessment of both the RT
and PCR steps and have shown promising results (JH and EL,
unpublished data) for the development of secondary reference
materials anchored to the primary reference standard for
quantitation of BCR–ABL1.
11
Cell line dilutions were also used to assess the assay analytical
precision. Duplicate testing across the assay linear dynamic
range resulted in 95% limits of agreement of plus or minus
2.4-fold, indicating that singleton test results are not very
different from the mean of duplicate testing (Figure 2d). As the
clinically relevant changes in BCR–ABL1 expression levels are at
minimum 2- to 10-fold and must be conﬁrmed by two
subsequent measurements within a period of a few months
before any change in therapeutic strategy,
1,2,20 these results
suggest that singleton testing should not affect the performance
of the assay for quantitative BCR–ABL1 reporting. This was
further conﬁrmed by evaluating precision on multiple days. The
standard curves were highly reproducible and most of the daily
means were within twofold of each other (Table 1). The within-
device variability, also called total precision (ST), combines the
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Figure 4 Evaluation of reference materials. (a) Ct values obtained for
each of the four samples tested in triplicate with the BCR/ABL1 Quant
assay (1000ng input). The linear regression curve and corresponding
equation and R
2 for BCR–ABL1 are shown. (b) Correlation between the
mean BCR–ABL1 and ABL1 percent ratios obtained for each sample
with the multiplex assay. The linear regression curve and correspond-
ing equation and R
2 are shown. The mean IS percent ratios reported by
White et al.
11 using three different endogenous control genes (ABL1,
BCR or GUS) are also shown.
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Blood Cancer Journalwithin-run (Sr) and between-day/run (Sdd) components of
precision,
12 resulting in percent coefﬁcients of variation higher
than with other commonly used methods such as the standard
deviation of all observed data or the standard deviation of
the daily means (used to calculate the percent coefﬁcients
of variation in Table 1). As expected, the contribution of
the within-run variability to the total precision at very low
BCR–ABL1 input was higher than the contribution of the
between-day/run variability (Table 2). This high variability near
the LOQ is consistent with the current limitations of quantitative
real-time technologies and is, in general, controlled in a clinical
setting by deﬁning reportable ranges and by not reporting
quantitative values below the validated assay LOQ (for example,
‘positive but below LOQ’).
By testing in singleton 115 archival total RNA samples from
monitored chronic myeloid leukemia patients, we further
showed that the BCR/ABL1 Quant assay is compatible with
representative clinical specimens, can detect the three different
BCR–ABL1 fusion transcripts in those specimens and has a high
qualitative and quantitative agreement with independent
singleplex LDTs routinely used in a clinical setting (Figure 3).
As the BCR–ABL1 and ABL1 transcripts have been shown to
have comparable mean stability,
13 a low ABL1 copy number
can indicate poor RNA quality and/or poor efﬁciency during the
extraction, RT or PCR steps. All of the residual RNA samples
evaluated had an ABL1 copy number compatible with
quantitative reporting, that is, 410
4 copies of ABL1 per reaction
and 450 copies of BCR–ABL1 for the few samples with o10
4
copies of ABL1 per reaction. Although the quantitative correla-
tion with each LDT was high (0.97), there was a signiﬁcant
difference in relative precision. The calculated mean bias
between methods or the mean difference between the log
percent ratio obtained with BCR/ABL1 Quant and each LDT was
0.21 and 1.07 for method 1 and method 2, respectively. In
agreement with previously reported data,
5 this observation
suggests that individual ﬁeld methods can generate widely
different percent ratios and further emphasizes the need for
reporting quantitative BCR–ABL1 measurements on a unique
standardized scale such as the IS.
As neither LDT was IS harmonized, we sought to directly
compare the assay with the IS using two distinct approaches.
Analysis of four-level reference materials conﬁrmed that multi-
plexing did not affect the sensitivity and linearity of the assay
(Figure 4). The BCR/ABL1 Quant percent ratios were all within
twofold of the reference IS percent ratios. However, it cannot be
concluded from this single experiment that there is a systematic
bias between the multiplex assay and a speciﬁc IS reference
method. The BCR–ABL1 to ABL1 IS percent ratios assigned to
these reference materials were obtained by averaging results
from six independent laboratories, and as much as fourfold
differences were observed between the different methods.
11 By
directly comparing the assay to a single IS reference method, we
found that there was a minimal bias between methods with two
lots of reagents (Figure 5). It should be emphasized that these
results do not imply that a CF of 1 can be systematically used to
convert percent ratio obtained with the BCR/ABL1 Quant assay
to IS percent ratio. Local laboratories reporting on the IS must
establish their own CF to factor in potential differences in
preanalytical steps and revalidate their CF every 2 years or each
time the procedure is changed.
7 In addition, the comparison
with the Reference Laboratory was performed using dilutions of
cell line RNA, whereas the recommended process is to perform
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Figure 5 Comparison with the international scale. (a) Bland and Altman analysis for the 20 samples tested with BCR/ABL1 Quant lot 1 at
Asuragen Inc. and by the reference method at the IS Reference Laboratory. The graph shows the difference between methods (log IS percent
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5 Therefore, the performance
reported here may not exactly mimic those of patient samples.
However, these results demonstrate that there is not a systematic
bias relative to the IS and validate that an analytical CF can be
maintained from lot-to-lot through rigorous manufacturing
procedures and quality controls.
The primary end point and key marker of molecular response
for imatinib and various second-generation tyrosine kinase
inhibitors is based on a single-point classiﬁcation, MMR, originally
deﬁned as a 3-log reduction in b2a2/b3a2 fusion transcripts from a
standardized baseline value and equivalent to 0.1% IS.
2–4
Previous work showed that quantitative assays must maintain
after IS conversion a mean bias relative to the reference method
between 0.8 and 1.2 (accuracy) and a reproducibility assessed by
the 95% limit of agreement within plus or minus ﬁvefold
(precision) to reach optimal MMR classiﬁcation accuracy.
5
MMR concordance rates of 91% are considered optimal given
the technical limitations of current technologies (95% limit of
agreement within plus or minus 2.5-fold for each method).
5 In our
experiments, we observed a mean bias after conversion of 0.96,
with 95% limits of agreement less than ﬁvefold and an overall
concordance rate of 74%. It is important to note that this last
performance metric is dependent not only on the analytical bias of
each method but also on the distribution of the tested samples
around the MMR point. In our sample set, the distribution was
relatively well balanced, with 57.5% (23/40) of the samples above
0.1% IS (MMR negative) and 42.5% (17/40) at or below 0.1% IS
(MMR positive) according to the reference method (Figure 5b).
However, 20% (8/40) of the samples had percent ratios very close
to the MMR cutoff point (within twofold or 0.05–0.2% IS ratio)
and 37.5% (15/40) of the samples were within ﬁvefold of MMR
(0.02–0.5% IS ratio). All samples misclassiﬁed had a BCR/ABL1
Quant IS percent ratio within the 95% limit of agreement between
methods, 80% of the samples had a difference of less than 2-fold
and one sample had an IS percent ratio 3.2-fold higher than the
reference method (Figure 5c). This variation was indistinguishable
from the inherent within-assay variability of both methods,
inferring that the observed concordance rate was likely optimal
for this sample set with the current quantitative RT-PCR
technologies.
In summary, our study established that the BCR/ABL1 Quant
research assay has the performance required for the sensitive
and multiplex detection of e1a2, b2a2, b3a2 and ABL1 and for
reporting quantitative measurement of BCR–ABL1 expression
levels on the IS. The assay, designed and manufactured under
current good manufacturing practises, is currently available as a
CE-marked test in Europe and as a Research Use Only assay in
the rest of the world. A multisite clinical validation study and
regulatory approval of a device based on a similar technology
would likely facilitate harmonization of BCR–ABL1 quantitative
measurement, improve clinical laboratories’ efﬁciency and work-
ﬂow, and increase adherence to the current recommendations for
reporting on the IS.
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